Key Highlights
- Veeva Systems skyrocketed 20% to reach $294.54, marking its strongest single-day percentage increase ever
- Second quarter FY2027 revenue reached $928 million, representing an 18% year-over-year increase and surpassing the $905 million analyst projection
- Adjusted earnings per share of $2.35 exceeded expectations of $2.22; annual EPS forecast elevated to $9.21
- Subscription-based revenue expanded 16% to $766.8 million; non-GAAP operating margins sustained levels exceeding 44%
- Major pharmaceutical companies Eli Lilly and Biogen adopted Vault CRM, increasing the count of top-20 biopharma clients utilizing the platform to 12
The life sciences cloud software provider Veeva Systems experienced its most impressive single-session performance on Thursday, with shares climbing 20% to close at $294.54. The remarkable surge followed the company’s fiscal second quarter 2027 report, which exceeded analyst expectations across all major performance indicators.
Veeva Systems Inc., VEEV
The company reported quarterly revenue of $928 million, reflecting an 18% year-over-year improvement and outperforming the Street’s $905 million projection. Adjusted earnings per share landed at $2.35, topping analyst estimates of $2.22.
Company leadership increased full-year FY2027 revenue projections to a range of $3.68-$3.69 billion, surpassing the previous Street consensus hovering around $3.65 billion. The adjusted EPS outlook for the full year was also upgraded to $9.21 from the earlier $9.05 forecast.
Subscription-based revenue, which represents Veeva’s most critical performance metric, expanded 16% year-over-year to reach $766.8 million. The company maintained non-GAAP operating margins above 44%, demonstrating that expansion isn’t sacrificing profitability.
Chief Executive Peter Gassner noted that “Vault CRM had its best quarter ever and Veeva Falcon accelerated rapidly,” further emphasizing that artificial intelligence is “opening up the next big chapter for Veeva and life sciences.”
During the quarter, two additional top-20 pharmaceutical companies, Eli Lilly and Biogen, selected Vault CRM for their operations. This milestone increases the total number of top-20 industry players using the platform to 12.
Following the quarterly results, close to 20 analyst firms upgraded their price targets for the stock.
Wall Street Response
Barclays analyst Saket Kalia elevated his price target to $315 from $275 while maintaining an Overweight rating. He highlighted the subscription revenue acceleration as a strong indicator of sustainable growth.
Piper Sandler launched coverage with an Overweight rating and $295 price target. Guggenheim increased its target to $310 from $276, maintaining a Buy rating, and described Veeva as “indispensable for its customers.”
Morgan Stanley analyst Craig Hettenbach boosted his target to $275 from $215. He identified the company’s upcoming investor day scheduled for November 5 as the next significant catalyst, characterizing it as “a referendum on the company’s AI strategy.”
Even more cautious analysts showed growing optimism. Canaccord increased its target to $260 from $220 while maintaining a Hold rating, describing the quarter as among the “cleanest” in recent memory.
Market Environment
Veeva’s impressive performance occurred alongside broader tech sector strength. Salesforce climbed more than 20% the same session after exceeding Q2 projections and expanding its Anthropic collaboration. ServiceNow and Datadog similarly recorded substantial gains.
Nvidia’s earnings report earlier in the week seemed to revitalize investor interest in technology and software equities broadly. The Nasdaq composite advanced 1.1% while the S&P 500 added 0.5% on Thursday.
Veeva ranked as the second-strongest performer within the S&P 500 during the session, trailing only Salesforce.
The stock traded in pre-market hours at $264, significantly above its session opening price of $239.87, before continuing its ascent throughout regular trading.
Veeva’s upcoming annual investor day on November 5 represents the next major corporate event, where executives are anticipated to provide comprehensive details regarding the company’s artificial intelligence roadmap.
The post Veeva Systems (VEEV) Stock Rockets 20% Following Record-Breaking Vault CRM Performance appeared first on Blockonomi.
Be the first to comment